US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ENGENE HOLDINGS INC

4.00

+0.01000.25%

Volume:71.68K

Turnover:287.49K

Market Cap:203.91M

PE:-2.59

High:4.39

Open:3.99

Low:3.90

Close:3.99

Loading ...

Overview Company News Filings

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

BRIEF-Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

enGene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Analysts Offer Insights on Real Estate Companies: Kimco Realty (KIM), Brixmor Property (BRX) and enGene Holdings (ENGN)

BUZZ-enGene Holdings rises after H.C. Wainwright starts coverage with 'buy'

enGene Holdings Price Target Maintained With a $18.00/Share by JMP Securities

HC Wainwright Initiates Coverage on enGene Holdings With Buy Rating, $25 Price Target

MT Newswires Live

enGene initiated with a Buy at H.C. Wainwright

enGene Holdings Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles

enGene Holdings: Entered Into Open Market Sale Agreement, May Offer & Sell Common Shares of up to $100 Mln - SEC Filing

THOMSON REUTERS

BRIEF-Engene Reports Full Year 2024 Financial Results And Provides A Business Update

enGene Holdings FY EPS $(1.46) Misses $(1.38) Estimate

enGene Holdings: Additional Preliminary Data From Pivotal Cohort Anticipated in 2H 2025

THOMSON REUTERS

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

THOMSON REUTERS

enGene Holdings: Bla Filing for Detalimogene in Bcg-Unresponsive Nmibc With CIS on Track for Mid-2026

THOMSON REUTERS

Press Release: enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene Holdings Price Target Maintained With a $18.00/Share by JMP Securities

enGene Holdings Initiated at Outperform by Raymond James

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENGN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENGN\",,,,,undefined,":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":4,"timestamp":1745524800000,"preClose":3.99,"halted":0,"volume":71676,"delay":0,"floatShares":24461393,"shares":50977560,"eps":-1.543739,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"04-25 05:44:04 EDT","open":3.99,"high":4.39,"low":3.9,"amount":287485.3484,"amplitude":0.122807,"askPrice":4.44,"askSize":6,"bidPrice":3.6,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.543739,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":4,"postHourTrading":{"tag":"盘后","latestPrice":4,"preClose":4,"latestTime":"16:05 EDT","volume":1,"amount":4,"timestamp":1745525108706},"volumeRatio":1.5720213653415869},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENGN\",,,,,undefined,":{"symbol":"ENGN","floatShares":24461393,"roa":"-25.75%","roe":"-44.21%","lyrEps":-1.459464,"volumeRatio":1.5720213653415869,"shares":50977560,"dividePrice":1.59238,"high":4.39,"amplitude":0.122807,"preClose":3.99,"low":3.9,"week52Low":3.5,"pbRate":"0.82","week52High":16.6189,"institutionHeld":0,"latestPrice":4,"committee":0.25,"eps":-1.543739,"divideRate":0.398095,"volume":71676,"delay":0,"ttmEps":-1.543739,"open":3.99,"prevYearClose":6.65,"prevWeekClose":4,"prevMonthClose":4.48,"prevQuarterClose":4.48,"fiveDayClose":3.96,"twentyDayClose":4.66,"sixtyDayClose":6.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENGN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507280116","title":"enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2507280116","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507280116?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242000,"startTime":"0","endTime":"0","summary":"Detalimogene voraplasmid is a novel, investigational, pivotal-stage, non-viral genetic medicine designed to mitigate systemic risks and deliver durable efficacy for patients with high-risk NMIBC, including Bacillus Calmette-Guérin -unresponsive disease. Ongoing, pivotal, registrational LEGEND study is actively enrolling patients with sites participating in the USA, Canada, Europe and the Asia-Pacific region. enGene’s Dually Derivatized Oligochitosan  platform is designed to potentially overcome the limitations of viral gene therapies and increase patient and clinician access to therapies. BOSTON & MONTREAL, January 30, 2025----enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid  is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin -unresponsive, non-muscle invasive bladder cancer  with carcinoma in situ , today announced three poster presentations at the 2025 ASCO Genitour","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-present-three-posters-2025-130000222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENGN","BCG","BK4135","ENGNW"],"gpt_icon":0},{"id":"2495503745","title":"BRIEF-Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495503745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495503745?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:24","pubTimestamp":1735593849,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Dec 30 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw4SFTRNaFurther company coverage: ENGN.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nTUA8SLVQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","BK4112","ENGN","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","BK4588","BK4585","BK4139","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2495503837","title":"enGene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495503837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495503837?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:05","pubTimestamp":1735592700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nTUA8SLVQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2210149790.SGD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","ENGN","BK4112","NDAQ","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2495850322","title":"enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495850322","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495850322?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:05","pubTimestamp":1735592700,"startTime":"0","endTime":"0","summary":"BOSTON & MONTREAL, December 30, 2024----enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, , is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin -unresponsive, non-muscle invasive bladder cancer  with carcinoma in situ , today reported the grant of inducement equity awards to five newly-hired employees, with a grant date of December 27, 2024.The stock options were granted by the Company's independent Compensation Committee of the Board of Directors as an inducement material to each new employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635. While the stock options were granted outside of the Company’s Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, each option will have terms and conditions consistent with those set forth under the Plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-reports-inducement-grants-under-210500806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENGN","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ","BK4585","LU2095319765.USD",".IXIC","BK4139","BCG","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","BK4135","BK4112","IE00BKPKM429.USD","ENGNW"],"gpt_icon":0},{"id":"2494289370","title":"Analysts Offer Insights on Real Estate Companies: Kimco Realty (KIM), Brixmor Property (BRX) and enGene Holdings (ENGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2494289370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494289370?lang=en_us&edition=fundamental","pubTime":"2024-12-25 21:31","pubTimestamp":1735133476,"startTime":"0","endTime":"0","summary":"Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Kimco Realty (KIM – Research Report), Brixmor Pro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-real-estate-companies-kimco-realty-kim-brixmor-property-brx-and-engene-holdings-engn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-real-estate-companies-kimco-realty-kim-brixmor-property-brx-and-engene-holdings-engn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","ENGN","BK4588","BRX","KIM","BK4231","BK4585","BK4139"],"gpt_icon":0},{"id":"2493761265","title":"BUZZ-enGene Holdings rises after H.C. Wainwright starts coverage with 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2493761265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493761265?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:25","pubTimestamp":1734967521,"startTime":"0","endTime":"0","summary":"BUZZ-enGene Holdings rises after H.C. Wainwright starts coverage with 'buy'** Drug developer enGene Holdings' ENGN.O shares rise 7.2% to $6.24 ** H.C. Wainwright starts coverage with \"buy\" rating and PT of $25 — a ~4x upside to Friday's close ** Brokerage says ENGN's lead drug, detalimogene, can be administered safer and simpler than other gene therapies ** ENGN reported in September that the drug had a complete response rate at any time of 71% in patients with high-risk non-muscle invasive bladder cancer** Brokerage says this is in-line with treatments from CG Oncology CGON.O and Johnson & Johnson JNJ.N** Complete response rate is the percentage of patients in a clinical trial whose cancer completely disappears after treatment.** Brokerage says investors should \"consider the holistic risk/reward profiles of treatments\" rather than focusing solely on the metric** Expects FDA approval for ENGN's drug by 2027 and sales of $868 mln by 2034** All ten brokerages rate stock \"buy\" or higher; ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nL4N3NO0RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","IE0002270589.USD","IE000M9KFDE8.USD","LU1032466523.USD","LU1929549753.HKD","LU2133065610.SGD","LU1914381329.SGD","BK4581","LU1023059063.AUD","BK4007","BK4532","LU1280957306.USD","LU1221951046.USD","LU1066053197.SGD","BK4550","LU0345770993.USD","LU1059921491.USD","IE00BGHQF631.EUR","LU1732799900.SGD","LU1267930813.SGD","BK4585","BK4139","LU1244550221.USD","LU1894683348.USD","LU1894683264.USD","SG9999002224.SGD","LU0203345920.USD","CGON","BK4534","JNJ","LU1778281490.HKD","LU2602419157.SGD","IE0009355771.USD","LU0792757196.USD","LU0234572021.USD","BK4592","LU0058720904.USD","LU0289739699.SGD","LU1074936037.SGD","BK4504","IE00B3PB1722.GBP","LU0882574055.USD","LU0122379950.USD","LU1066051811.HKD","LU0795875086.SGD","LU1732800096.USD","IE00BSNM7G36.USD","LU0320765646.SGD","LU1261432733.SGD","LU0345769631.USD"],"gpt_icon":0},{"id":"2493768863","title":"enGene Holdings Price Target Maintained With a $18.00/Share by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768863","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768863?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:53","pubTimestamp":1734961980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 08:53 ET (13:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","JMP"],"gpt_icon":0},{"id":"2493759153","title":"HC Wainwright Initiates Coverage on enGene Holdings With Buy Rating, $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2493759153","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493759153?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:16","pubTimestamp":1734956171,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of Buy and mean price target of $27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN"],"gpt_icon":0},{"id":"2493535117","title":"enGene initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2493535117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493535117?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:05","pubTimestamp":1734951909,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Maldonado initiated coverage of enGene (ENGN) with a Buy rating and $25 price target The firm says the The non-muscl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2493675834","title":"enGene Holdings Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2493675834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493675834?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:03","pubTimestamp":1734951807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nAZN2WWC0R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2493620281","title":"Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2493620281","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493620281?lang=en_us&edition=fundamental","pubTime":"2024-12-21 14:00","pubTimestamp":1734760807,"startTime":"0","endTime":"0","summary":"Engene Holdings Inc. (ENGN) has disclosed a new risk, in the Innovation / R&D category. Engene Holdings Inc. faces significant business risks due t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/engene-holdings-faces-regulatory-challenges-and-business-risks-amid-clinical-trial-hurdles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/engene-holdings-faces-regulatory-challenges-and-business-risks-amid-clinical-trial-hurdles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2492742411","title":"enGene Holdings: Entered Into Open Market Sale Agreement, May Offer & Sell Common Shares of up to $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2492742411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492742411?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:59","pubTimestamp":1734695946,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NK1GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2492484635","title":"BRIEF-Engene Reports Full Year 2024 Financial Results And Provides A Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492484635","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492484635?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:24","pubTimestamp":1734643460,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Reports Full Year 2024 Financial Results And Provides A Business UpdateDec 19 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A BUSINES","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA4FYQ7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2492811154","title":"enGene Holdings FY EPS $(1.46) Misses $(1.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2492811154","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492811154?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:12","pubTimestamp":1734642760,"startTime":"0","endTime":"0","summary":"enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.38) by 5.8 percent. This is a 99.03 percent increase over losses of $(151.22) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42604002/engene-holdings-fy-eps-1-46-misses-1-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"enGene Holdings FY EPS $(1.46) Misses $(1.38) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN"],"gpt_icon":0},{"id":"2492811694","title":"enGene Holdings:  Additional Preliminary Data From Pivotal Cohort Anticipated in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492811694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492811694?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:05","pubTimestamp":1734642301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA4FYQ7L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2492559481","title":"enGene Reports Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492559481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492559481?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:05","pubTimestamp":1734642301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA4FYQ7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2492152481","title":"enGene Holdings: Bla Filing for Detalimogene in Bcg-Unresponsive Nmibc With CIS on Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2492152481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492152481?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:05","pubTimestamp":1734642301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA4FYQ7L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2492595481","title":"Press Release: enGene Reports Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492595481","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492595481?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:05","pubTimestamp":1734642300,"startTime":"0","endTime":"0","summary":"BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026. All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol. Additional preliminary data from pivotal cohort anticipated in 2H 2025. Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027. \"Having demonstrated a 71% anytime complete response rate in the preliminary data from the LEGEND study's pivotal cohort of BCG-unresponsive NMIBC patients, initiated three additional NMIBC patient cohorts, and raised an additional $60 million in funding, enGene is in a strong clinical and financial position as we close the year,\" said Ron Cooper, Chief Executive Officer of enGene. \"With trial recruitment open across all cohorts, the profile of detalimogene continues to become clearer and stronger and, with the protocol enhancements now in place, we look forward to sharing LEGEND study updates across all cohorts expected in the second half of 2025.\". LEGEND stud","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN","CR","CTO","BCG","BK4135","BK4161","BK4160"],"gpt_icon":0},{"id":"2489238244","title":"enGene Holdings Price Target Maintained With a $18.00/Share by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2489238244","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489238244?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:44","pubTimestamp":1733492640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 08:44 ET (13:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JMP","ENGN"],"gpt_icon":0},{"id":"2486787475","title":"enGene Holdings Initiated at Outperform by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2486787475","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486787475?lang=en_us&edition=fundamental","pubTime":"2024-11-28 00:54","pubTimestamp":1732726440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 27, 2024 11:54 ET (16:54 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","RJF"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-10","symbol":"ENGN","fiscalQuarterEnding":"2025/01","expectedEps":-0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-12-19","symbol":"ENGN","fiscalQuarterEnding":"2024/10","expectedEps":-0.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1734584400000,"reportTimeType":"post","actualEps":-0.34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.5455,"hold":0.0909,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1739851200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENGN","date":"2025-04-24","current":-2.945826,"percent":0.797619,"low":-11.074501,"twenty":-6.747259,"median":-4.27293,"eighty":-2.945826,"high":-1.741293,"avg":-4.786127,"sd":1.94014,"marketCap":203400464},"quantilePoints":[{"date":"2023-11-24","current":-7.107113,"twenty":-7.362609,"median":-7.152095,"eighty":-7.017149,"marketCap":183264010},{"date":"2023-12-01","current":-6.8912,"twenty":-7.362609,"median":-7.170087,"eighty":-7.020748,"marketCap":177696496},{"date":"2023-12-08","current":-6.666292,"twenty":-8.564557,"median":-7.174585,"eighty":-6.887602,"marketCap":171897002},{"date":"2023-12-15","current":-6.641012,"twenty":-7.798032,"median":-7.107113,"eighty":-6.607942,"marketCap":171245139},{"date":"2023-12-22","current":-6.504358,"twenty":-7.362609,"median":-6.814731,"eighty":-6.515153,"marketCap":167721366},{"date":"2023-12-29","current":-7.296036,"twenty":-7.276244,"median":-6.747259,"eighty":-6.432387,"marketCap":188135585},{"date":"2024-01-05","current":-6.405398,"twenty":-7.70447,"median":-6.814731,"eighty":-6.412595,"marketCap":165169589},{"date":"2024-01-12","current":-7.251054,"twenty":-7.438178,"median":-6.882204,"eighty":-6.486365,"marketCap":186975686},{"date":"2024-01-19","current":-7.197076,"twenty":-7.362609,"median":-6.882204,"eighty":-6.515153,"marketCap":185583808},{"date":"2024-01-26","current":-6.837222,"twenty":-7.314029,"median":-6.823728,"eighty":-6.515153,"marketCap":176304617},{"date":"2024-02-02","current":-1.959536,"twenty":-7.276604,"median":-6.810233,"eighty":-6.462974,"marketCap":195790917},{"date":"2024-02-09","current":-1.845771,"twenty":-7.256092,"median":-6.76975,"eighty":-6.369412,"marketCap":184423909},{"date":"2024-02-16","current":-3.645108,"twenty":-7.218667,"median":-6.747259,"eighty":-3.756551,"marketCap":364208223},{"date":"2024-02-23","current":-6.848243,"twenty":-7.197076,"median":-6.729266,"eighty":-3.686899,"marketCap":684255939},{"date":"2024-03-01","current":-6.376994,"twenty":-7.189879,"median":-6.715257,"eighty":-3.782089,"marketCap":637170146},{"date":"2024-03-08","current":-6.913094,"twenty":-7.175485,"median":-6.740159,"eighty":-4.788696,"marketCap":690735636},{"date":"2024-03-15","current":-7.043277,"twenty":-7.155487,"median":-6.747259,"eighty":-6.236267,"marketCap":726936601},{"date":"2024-03-22","current":-7.516207,"twenty":-7.197076,"median":-6.792241,"eighty":-6.288445,"marketCap":775747691},{"date":"2024-03-28","current":-7.279742,"twenty":-7.276523,"median":-6.837222,"eighty":-6.349337,"marketCap":751342146},{"date":"2024-04-05","current":-6.925044,"twenty":-7.26113,"median":-6.876032,"eighty":-6.379076,"marketCap":714733828},{"date":"2024-04-12","current":-6.874373,"twenty":-7.240258,"median":-6.870151,"eighty":-6.391004,"marketCap":709504068},{"date":"2024-04-19","current":-5.983407,"twenty":-7.197076,"median":-6.842733,"eighty":-6.391004,"marketCap":617547460},{"date":"2024-04-26","current":-6.289752,"twenty":-7.193478,"median":-6.810233,"eighty":-6.342947,"marketCap":649165336},{"date":"2024-05-03","current":-6.546128,"twenty":-7.177285,"median":-6.792241,"eighty":-6.351434,"marketCap":675625879},{"date":"2024-05-10","current":-6.153019,"twenty":-7.167527,"median":-6.747259,"eighty":-6.342947,"marketCap":635053046},{"date":"2024-05-17","current":-6.063287,"twenty":-7.153064,"median":-6.743709,"eighty":-6.259918,"marketCap":625791856},{"date":"2024-05-24","current":-5.614629,"twenty":-7.135657,"median":-6.708499,"eighty":-6.098325,"marketCap":579485904},{"date":"2024-05-31","current":-4.486576,"twenty":-7.133587,"median":-6.688278,"eighty":-6.063287,"marketCap":463059513},{"date":"2024-06-07","current":-3.360659,"twenty":-7.131951,"median":-6.661794,"eighty":-5.648813,"marketCap":346853625},{"date":"2024-06-14","current":-4.27293,"twenty":-7.118439,"median":-6.651549,"eighty":-5.484732,"marketCap":441009060},{"date":"2024-06-21","current":-3.406965,"twenty":-7.110292,"median":-6.643683,"eighty":-5.017274,"marketCap":384687244},{"date":"2024-06-28","current":-3.508666,"twenty":-7.107113,"median":-6.634163,"eighty":-4.27293,"marketCap":396170446},{"date":"2024-07-05","current":-3.516489,"twenty":-7.107113,"median":-6.621073,"eighty":-3.815858,"marketCap":397053769},{"date":"2024-07-12","current":-3.5204,"twenty":-7.093203,"median":-6.587237,"eighty":-3.642484,"marketCap":397495431},{"date":"2024-07-15","current":-3.547781,"twenty":-7.089725,"median":-6.572786,"eighty":-3.63199,"marketCap":400587062},{"date":"2024-08-02","current":-3.446081,"twenty":-7.089604,"median":-6.558336,"eighty":-3.589657,"marketCap":389103860},{"date":"2024-08-09","current":-2.777205,"twenty":-7.088397,"median":-6.52142,"eighty":-3.527005,"marketCap":313579728},{"date":"2024-08-16","current":-2.307818,"twenty":-7.080829,"median":-6.504358,"eighty":-3.517271,"marketCap":260580338},{"date":"2024-08-23","current":-2.370403,"twenty":-7.05836,"median":-6.454878,"eighty":-3.458598,"marketCap":267646923},{"date":"2024-08-30","current":-2.573804,"twenty":-7.039722,"median":-6.405398,"eighty":-3.383305,"marketCap":290613326},{"date":"2024-09-06","current":-2.554246,"twenty":-7.025502,"median":-6.379484,"eighty":-3.290156,"marketCap":288405018},{"date":"2024-09-13","current":-2.400727,"twenty":-6.984161,"median":-6.343733,"eighty":-3.031456,"marketCap":293704957},{"date":"2024-09-20","current":-2.587735,"twenty":-6.954602,"median":-6.302571,"eighty":-2.628566,"marketCap":316583531},{"date":"2024-09-27","current":-1.987785,"twenty":-6.936182,"median":-6.238965,"eighty":-2.585538,"marketCap":243185673},{"date":"2024-10-04","current":-2.349201,"twenty":-6.925044,"median":-6.153019,"eighty":-2.573804,"marketCap":287401250},{"date":"2024-10-11","current":-2.479311,"twenty":-6.921741,"median":-6.080379,"eighty":-2.554246,"marketCap":303318858},{"date":"2024-10-18","current":-3.361165,"twenty":-6.921741,"median":-5.983407,"eighty":-2.554246,"marketCap":411204866},{"date":"2024-10-25","current":-3.216598,"twenty":-6.91854,"median":-5.659496,"eighty":-2.56605,"marketCap":393518635},{"date":"2024-10-31","current":-3.137087,"twenty":-6.914183,"median":-5.580446,"eighty":-2.572253,"marketCap":383791208},{"date":"2024-11-08","current":-3.035891,"twenty":-6.895579,"median":-5.443712,"eighty":-2.573804,"marketCap":371410846},{"date":"2024-11-15","current":-3.304095,"twenty":-6.884003,"median":-4.928824,"eighty":-2.580062,"marketCap":404222931},{"date":"2024-11-22","current":-3.195938,"twenty":-6.875939,"median":-4.2302,"eighty":-2.584756,"marketCap":390991104},{"date":"2024-11-29","current":-3.604285,"twenty":-6.87184,"median":-3.830846,"eighty":-2.585538,"marketCap":440948247},{"date":"2024-12-06","current":-3.600118,"twenty":-6.869976,"median":-3.719091,"eighty":-2.585538,"marketCap":440438480},{"date":"2024-12-13","current":-2.745924,"twenty":-6.85689,"median":-3.63199,"eighty":-2.586856,"marketCap":335936294},{"date":"2024-12-20","current":-2.483415,"twenty":-6.84163,"median":-3.604285,"eighty":-2.585538,"marketCap":303820988},{"date":"2024-12-27","current":-5.676196,"twenty":-6.836881,"median":-3.618138,"eighty":-2.585538,"marketCap":312996790},{"date":"2025-01-03","current":-6.526701,"twenty":-6.831143,"median":-3.666853,"eighty":-2.585977,"marketCap":359895332},{"date":"2025-01-10","current":-7.488141,"twenty":-6.86986,"median":-3.752745,"eighty":-2.587735,"marketCap":412911075},{"date":"2025-01-17","current":-6.480478,"twenty":-6.874373,"median":-4.2302,"eighty":-2.598578,"marketCap":357346498},{"date":"2025-01-24","current":-6.739327,"twenty":-6.870995,"median":-4.27293,"eighty":-2.60436,"marketCap":371619968},{"date":"2025-01-31","current":-6.563679,"twenty":-6.869918,"median":-5.380342,"eighty":-2.617897,"marketCap":361934399},{"date":"2025-02-07","current":-5.870333,"twenty":-6.868974,"median":-5.443712,"eighty":-2.624253,"marketCap":323701892},{"date":"2025-02-14","current":-5.777887,"twenty":-6.852345,"median":-5.580446,"eighty":-2.62701,"marketCap":318604225},{"date":"2025-02-21","current":-5.657707,"twenty":-6.84163,"median":-5.580446,"eighty":-2.628136,"marketCap":311977257},{"date":"2025-02-28","current":-5.398857,"twenty":-6.836711,"median":-5.546263,"eighty":-2.689586,"marketCap":297703787},{"date":"2025-03-07","current":-4.908892,"twenty":-6.833612,"median":-5.507012,"eighty":-2.739661,"marketCap":270686149},{"date":"2025-03-14","current":-3.949849,"twenty":-6.818849,"median":-5.443712,"eighty":-2.748264,"marketCap":272725216},{"date":"2025-03-21","current":-3.846555,"twenty":-6.800468,"median":-5.398857,"eighty":-2.766253,"marketCap":265593087},{"date":"2025-03-28","current":-3.506936,"twenty":-6.792928,"median":-5.371072,"eighty":-2.784959,"marketCap":242143410},{"date":"2025-04-04","current":-3.32236,"twenty":-6.792241,"median":-5.209343,"eighty":-2.829161,"marketCap":229399020},{"date":"2025-04-11","current":-2.953209,"twenty":-6.790707,"median":-4.908892,"eighty":-2.913999,"marketCap":203910240},{"date":"2025-04-17","current":-2.923677,"twenty":-6.772715,"median":-4.84418,"eighty":-2.93549,"marketCap":201871137},{"date":"2025-04-24","current":-2.945826,"twenty":-6.747259,"median":-4.27293,"eighty":-2.945826,"marketCap":203400464}],"updateTime":1745574244037}}}